Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet · 2014
Cited by 1,663 works. doi:10.1016/s0140-6736(14)60421-9
Authors
- Marcia S. Brose
- Christopher M. Nutting
- Barbara Jarząb
- Rossella Elisei
- Salvatore Siena
- Lars Bastholt
- Christelle de la Fouchardière
- Furio Pacini
- Ralf Paschke
- Young Kee Shong
- Steven I. Sherman
- Johannes W. A. Smit
- John Chung
- Christian Kappeler
- Carol Peña
- István Molnár
- Martin Jean Schlumberger
References
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- Sorafenib in Advanced Hepatocellular Carcinoma
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- Sorafenib in Advanced Hepatocellular Carcinoma
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy
- BAY 43-9006 Inhibition of Oncogenic RET Mutants
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- Molecular pathogenesis and mechanisms of thyroid cancer